{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Delgado-Ortiz L"],"funding":["Societat Catalana de Pneumologia","Innovative Medicines Initiative","Instituto de Salud Carlos III","Sociedad Española de Neumología y Cirugía Torácica"],"pagination":["00673-2023"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10910309"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(2)"],"pubmed_abstract":["<h4>Introduction</h4>The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence.<h4>Methods</h4>We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7 days' accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries.<h4>Results</h4>Participants were mostly male (80%) and had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV<sub>1</sub>) of 57±19% predicted and walked 6880±3926 steps·day<sup>-1</sup>. Mean walking cadence was 88±9 steps·min<sup>-1</sup>, followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90-0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV<sub>1,</sub> 6-min walk distance, physical activity (steps·day<sup>-1</sup>, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min<sup>-1</sup>, 95% CI 0.91-0.99, p=0.009).<h4>Conclusions</h4>Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome."],"journal":["ERJ open research"],"pubmed_title":["Real-world walking cadence in people with COPD."],"pmcid":["PMC10910309"],"funding_grant_id":["115011","FI21/00113","PI11/ 01283","820820","201/2011","147/2011","Ajuts al millor projecte en fisioteràpia respirat","PI14/0419"],"pubmed_authors":["Karlsson N","Arbillaga-Etxarri A","Rodriguez Chiaradia DA","Demeyer H","Buekers J","Polkey MI","Balcells E","Hopkinson NS","Troosters T","Rabinovich RA","Garcia-Aymerich J","Gimeno-Santos E","de Jong C","Rodriguez-Roisin R","Palmerini L","Toran-Montserrat P","Frei A","Vogiatzis I","Louvaris Z","Delgado-Ortiz L","Watz H","Ranciati S","Puhan MA"],"additional_accession":[]},"is_claimable":false,"name":"Real-world walking cadence in people with COPD.","description":"<h4>Introduction</h4>The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence.<h4>Methods</h4>We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7 days' accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries.<h4>Results</h4>Participants were mostly male (80%) and had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV<sub>1</sub>) of 57±19% predicted and walked 6880±3926 steps·day<sup>-1</sup>. Mean walking cadence was 88±9 steps·min<sup>-1</sup>, followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90-0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV<sub>1,</sub> 6-min walk distance, physical activity (steps·day<sup>-1</sup>, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min<sup>-1</sup>, 95% CI 0.91-0.99, p=0.009).<h4>Conclusions</h4>Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-09T07:02:07.012Z","creation":"2026-06-09T03:12:18.768Z"},"accession":"S-EPMC10910309","cross_references":{"pubmed":["38444656"],"doi":["10.1183/23120541.00673-2023"]}}